Sign in
Active, not recruitingPhase 2

Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

Key facts

Who runs it
Eagle Pharmaceuticals, Inc.
Where
Chicago, Cleveland, Fresno, Gainesville, Galveston, Omaha, and Winston-Salem, United StatesSee the 7 sitesAlso in 18 other countries, 83 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
276 people, planned
Started
22 Jul 2023
Ended
7 Sept 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • CAL02
  • Placebo
Record updated
28 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • male or females older than 18 years old
  • Body Weight 40 - 140 kg
  • clinical diagnosis of CABP diagnosed less than or equal to 48 hrs after hospital admission
  • presence of at least one of the protocol defined SCABP severity criteria:
  • at least two clinical symptoms
  • at least 2 vital sign abnormalities
  • at least one finding of other clinical signs/laboratory abnormalities
  • radiographic evidence in support of pneumonia with likely bacterial origin
  • presence of at least one of the following severity criteria based on protocol defined SCABP:
  • respiratory failure requiring invasive mechanical ventilation support
  • respiratory failure requiring non-invasive positive pressure ventilation support
  • respiratory failure requiring high-flow oxygen
  • septic shock requiring treatment with vasopressors at therapeutic doses for at least 2 hours
  • requires critical care for management of SCABP
  • onset of severity criteria less than 48 hours from diagnosis of CABP or upon discussion with medical monitor
  • written informed consent before any study-specific assessment is performed

Who cannot take part

  • subject received IV antibiotics for CABP/SCABP for more than 48 hours at the time of randomization if sensitivity supports appropriate empiric therapy chosen and administered
  • renal replacement therapy
  • known hypersensitivity to liposomal formulations
  • end-stage neuromuscular disorders, tracheostomy, known bronchial obstruction, post-operative aspiration pneumonia, cystic fibrosis, known or suspected pneumocystis jirovecii or tuberculosis pneumonia, post organ transplant, or primary or metastatic malignancy in the lungs
  • known liver dysfunction, chronic liver disease with Child Pugh C or esophageal varices
  • moribund clinical conditions at the time of screening or time of the first study medication infusion
  • subject has any medical disease or condition that, in the opinion of the investigator, compromises the subject's safety or compromises the interpretation of results
  • subjects with ventilator-associated pneumonia, aspiration pneumonia, fungal pneumonia, viral pneumonia (viral coinfection may be exempted subject to discussion with medical monitor)
  • subjects more than 12 hours from the diagnosis of SCABP
  • SOFA score greater than 12 points
  • current or recent participation in an investigational study (within 30 days of screening or 5 half-lives of the investigational compound, whichever is longer)
  • refractory septic shock at the time of randomization
  • nursing and pregnant women
  • women of childbearing potential and non-surgically sterile males

Where in United States

Also in 18 other countries, 83 sites

  • Northwestern Memorial HospitalChicago, United States
  • Cleveland Clinic Fairview HospitalCleveland, United States
  • UCSF HospitalFresno, United States
  • UF Health Shands HospitalGainesville, United States
  • University of Texas Medical BranchGalveston, United States
  • University of Nebraska Medical CenterOmaha, United States
  • Wake Forest Baptist Health HospitalWinston-Salem, United States

About the trial

What the trial wants to find out

This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures

The 2 groups in the trial

  • CAL02 with Standard of CareTreatment being tested

    CAL02 (a mixture of 2 liposomal components, both empty, unilamellar, liposomes) will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. CAL02 infusions will be administered over a 1 -2 hour period.

    Treatment: CAL02

  • PlaceboPlacebo, for comparison

    Placebo will be administered as 2, IV infusions, 24 - 26 hours apart in addition to Standard of Care therapy for SCABP, according to scientific guidelines. Placebo will be prepared and administered following the same infusion protocol as CAL02. Placebo infusions will be administered over a 1 to 2 hour period.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects With Severe Community-Acquired Bacterial Pneumonia (SCABP)
Record updated
28 January 2026